KINGSBRIDGE HEALTHCARE GROUP LIMITED

• ◆

  2 PSCs ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Accordingly, the directors believe it is appropriate to continue to adopt the going concern basis in preparing the financial statements.”

Group structure

1. KINGSBRIDGE HEALTHCARE GROUP LIMITED · parent
   1. Kingsbridge Private Hospital Belfast Limited 100% · Northern Ireland · Provision of medical services
   2. 352 Medical Limited 100% · Northern Ireland · Dormant company
   3. Kingsbridge Private Hospital Sligo Limited 100% · Republic of Ireland · Provision of medical services
   4. Kingsbridge Private Hospital North West Limited 100% · Northern Ireland · Provision of medical services
   5. Kingsbridge Opticians & Hearing Clinic Limited 100% · Northern Ireland · Opticians and ear specialists
   6. Cosmetech Clinics Limited 100% · Northern Ireland · Provision of medical services
   7. Dataworks Management Company Limited 50% · Northern Ireland · Management of real estate on a fee or contract basis
   8. Chelsea Private Clinic Limited 100% · Northern Ireland · Other human health activities

Significant events

• “On 8 August 2024, the Group completed the sale of a significant stake to London-based private equity firm, Exponent. This investment will support our growth ambitions in delivering world-class medical services across the island of Ireland and expanding access to a wider range of treatments.”
• “Northern Ireland's first cardiac Cath Lab in Belfast, complementing existing cardiac services.”
• “A new satellite clinic in Newry to provide rapid-access diagnostics and outpatient care for cross-border patients.”
• “Development sites in Belfast and Sligo, with planning approvals in place for future hospital expansions.”
• “On 9 August 2024, the Company issued 82,478 ordinary 'C' shares of £0.01 each for a total consideration of £500,169.”
• “On 28 October 2024, the Company by passing a special resolution altered the share capital by redesignation of 498,742 ordinary 'A' shares, 498,742 ordinary 'B' shares, 84,994 ordinary 'C' shares, 258,131 ordinary 'D' shares and 29,358 growth shares of £0.01 each in the capital of the Company to 1,369,967 ordinary shares of £0.01 each in the capital of the Company.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

2

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.